microRNA‑199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mammalian target of rapamycin

Wang,Zhongxian; Ting,Zhou; Li,Ya; Chen,Gang; Lu,Yunping; Hao,Xing

doi:10.3892/ol.2013.1448

September 2013 Volume 6 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September 2013 Volume 6 Issue 3

Full Size Image

Article

microRNA‑199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mammalian target of rapamycin

Authors:
- Zhongxian Wang
- Zhou Ting
- Ya Li
- Gang Chen
- Yunping Lu
- Xing Hao
View Affiliations / Copyright

Affiliations: Department of Obstetrics and Gynecology, The First College of Clinical Medical Sciences and Yichang Central People's Hospital, China Three Gorges University, Yichang, Hubei, P.R. China, Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P.R. China
Pages: 789-794
|
Published online on: July 8, 2013

https://doi.org/10.3892/ol.2013.1448
Expand metrics +

Abstract

microRNAs (miRNAs/miRs) may have a crucial function in tumor metastasis through the regulation of a plethora of signaling pathways. Increasing evidence has shown that miR‑199a is important in regulating the tumor metastasis of ovarian cancer, although the precise biological function of miR‑199a is unclear at present. In the current study, it was observed that the expression levels of miR‑199a were higher in OV2008 cells compared with C13* cells. However, lower levels of mammalian target of rapamycin (mTOR) protein were detected by western blotting in the OV2008 cells compared with the C13* cells. The miR‑199a levels were increased in the C13* cells using miR‑199a mimics and the mTOR levels were observed to decrease. This may have resulted in a reversal of cisplatin resistance in the C13* cells. To test this hypothesis, the Renilla luciferase reporter gene system was used to analyze the mTOR levels. The results indicated that the expression levels of mTOR were significantly blocked by the increased miR‑199a levels. When the miR‑199a inhibitor was applied to decrease the miR‑199a levels, it was observed that the mTOR expression levels were increased, while cisplatin‑induced apoptosis was decreased in the OV2008 cells. The study concludes that miR‑199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mTOR and that mTOR may be the target of miR‑199a during this process.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2	Wangpaichitr M, Wu C, You M, et al: Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Eur J Pharmacol. 591:124–127. 2008. View Article : Google Scholar : PubMed/NCBI
3	Nam EJ, Yoon H, Kim SW, et al: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 14:2690–2695. 2008. View Article : Google Scholar : PubMed/NCBI
4	Torres A, Torres K, Maciejewski R and Harvey WH: MicroRNAs and their role in gynecological tumors. Med Res Rev. 31:895–923. 2010. View Article : Google Scholar : PubMed/NCBI
5	Cho WC: Updates in cancer research: insights from the AACR 100th Annual Meeting. Expert Rev Mol Diagn. 9:411–416. 2009. View Article : Google Scholar : PubMed/NCBI
6	Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
7	Fornari F, Milazzo M, Chieco P, et al: MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 70:5184–5193. 2010. View Article : Google Scholar : PubMed/NCBI
8	Hou J, Lin L, Zhou W, et al: Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell. 19:232–243. 2011. View Article : Google Scholar
9	Castedo M, Ferri KF and Kroemer G: Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ. 9:99–100. 2002. View Article : Google Scholar : PubMed/NCBI
10	Castedo M, Roumier T, Blanco J, et al: Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. EMBO J. 21:4070–4080. 2002. View Article : Google Scholar : PubMed/NCBI
11	Li X, Alafuzoff I, Soininen H, Winblad B and Pei JJ: Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer’s disease brain. FEBS J. 272:4211–4220. 2005.PubMed/NCBI
12	Zivny J, Klener P Jr, Pytlik R and Andera L: The role of apoptosis in cancer development and treatment: focusing on the development and treatment of hematologic malignancies. Curr Pharm Des. 16:11–33. 2010. View Article : Google Scholar
13	Tsurutani J, West KA, Sayyah J, Gills JJ and Dennis PA: Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res. 65:8423–8432. 2005. View Article : Google Scholar
14	Tam KH, Yang ZF, Lau CK, Lam CT, Pang RW and Poon RT: Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Lett. 273:201–209. 2009. View Article : Google Scholar : PubMed/NCBI
15	Mazzoletti M and Broggini M: PI3K/AKT/mTOR inhibitors in ovarian cancer. Curr Med Chem. 17:4433–4447. 2010. View Article : Google Scholar : PubMed/NCBI
16	Peng DJ, Wang J, Zhou JY and Wu GS: Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem Biophys Res Commun. 394:600–605. 2010. View Article : Google Scholar : PubMed/NCBI
17	Zhang HY, Zhang PN and Sun H: Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy. Eur J Obstet Gynecol Reprod Biol. 146:81–86. 2009. View Article : Google Scholar : PubMed/NCBI
18	Foster H, Coley HM, Goumenou A, Pados G, Harvey A and Karteris E: Differential expression of mTOR signalling components in drug resistance in ovarian cancer. Anticancer Res. 30:3529–3534. 2010.PubMed/NCBI
19	Wahid F, Shehzad A, Khan T and Kim YY: MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta. 1803:1231–1243. 2010. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

microRNA‑199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mammalian target of rapamycin

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles